Emergent Biosolutions Inc (EBS) Gross Profit Margin starting from the second quarter 2026 to second quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Emergent Biosolutions Inc   (NYSE: EBS)


Emergent Biosolutions Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EBS Gross Profit Margin (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3 		(Jun 30 2025)
Q2
Y / Y Revenue Change 66.29 %
Seq. Revenue Change 50.1 %
Revenue In Millions $234.30
Gross Profit Margin 58.56 %
Gross Profit Margin Total Ranking # 1577
Gross Profit In Millions $137.20
Y / Y Gross Profit Change 85.41 %
Seq. Gross Profit Change 63.14 %


Commenting Second Quarter 2026 Gross Profit Margin
Emergent Biosolutions Inc Gross Profit grew by 63.14 % in Q2 sequentially to 137 millions, while Revenue increased by 50.1 %, this led to improvement in the company's Gross Profit Margin to 58.56 %, Gross Profit Margin remained below Emergent Biosolutions Inc average.


Observing second quarter 2026 results within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1577, from total ranking in the previous quarter at 2139.
Learn about Gross Margin
EBS's Gross Profit Margin second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 290
Overall # 1566

Gross Profit Margin Statistics
High Average Low
93.41 % 60.41 % 4.14 %
(Dec 31 2021)   (Dec 31 2018)


EBS Gross Income Trends • More of EBS's Profitabilty Ratios • EBS Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
EBS's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
EBS's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for EBS's Competitors
Gross Profit Margin Profit Margin for Emergent Biosolutions Inc 's Suppliers
Gross Profit Margin Profit Margin for EBS's Customers

You may also want to know
EBS's Annual Growth Rates EBS's Profitability Ratios EBS's Asset Turnover Ratio EBS's Dividend Growth
EBS's Roe EBS's Valuation Ratios EBS's Financial Strength Ratios EBS's Gross Profit Growth
EBS's Roa EBS's Inventory Turnover Ratio EBS's Growth Rates EBS's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2026 MRQ Gross ProfitJun 30 2026 MRQ Revenue
Vireo Growth Inc.  99.81 %$ 208.900  Millions$ 209.300  Millions
Ptc Therapeutics inc   99.75 %$ 359.619  Millions$ 360.519  Millions
Crinetics Pharmaceuticals Inc   99.39 %$ 24.964  Millions$ 25.118  Millions
Verastem Inc   99.30 %$ 39.799  Millions$ 40.078  Millions
Adc Therapeutics Sa  99.11 %$ 19.077  Millions$ 19.248  Millions
Ionis Pharmaceuticals Inc   98.98 %$ 265.210  Millions$ 267.949  Millions
Biofrontera Inc   98.88 %$ 11.868  Millions$ 12.003  Millions
Kura Oncology Inc   98.84 %$ 20.631  Millions$ 20.874  Millions
Travere Therapeutics Inc   98.72 %$ 167.410  Millions$ 169.584  Millions
Corcept Therapeutics Inc  98.41 %$ 252.086  Millions$ 256.147  Millions
Ovid Therapeutics Inc   97.82 %$ 0.717  Millions$ 0.733  Millions
Scienture Holdings Inc   97.71 %$ 0.336  Millions$ 0.344  Millions
Madrigal Pharmaceuticals Inc   97.14 %$ 353.852  Millions$ 364.252  Millions
Sarepta Therapeutics Inc   97.11 %$ 389.651  Millions$ 401.251  Millions
Zevra Therapeutics Inc   96.16 %$ 38.138  Millions$ 39.663  Millions
Ardelyx inc   95.24 %$ 115.118  Millions$ 120.877  Millions
Tonix Pharmaceuticals Holding Corp   94.81 %$ 12.841  Millions$ 13.544  Millions
Lexicon Pharmaceuticals Inc   94.36 %$ 0.653  Millions$ 0.692  Millions
Milestone Pharmaceuticals Inc   94.28 %$ 0.527  Millions$ 0.559  Millions
Bridgebio Pharma Inc   93.83 %$ 228.630  Millions$ 243.676  Millions
Axsome Therapeutics Inc   93.79 %$ 204.811  Millions$ 218.375  Millions
Agios Pharmaceuticals Inc   93.30 %$ 41.749  Millions$ 44.745  Millions
Vanda Pharmaceuticals Inc   92.95 %$ 46.969  Millions$ 50.529  Millions
Gyre Therapeutics Inc   92.41 %$ 26.896  Millions$ 29.105  Millions
Aurinia Pharmaceuticals Inc   92.12 %$ 76.665  Millions$ 83.220  Millions
Arcutis Biotherapeutics Inc   91.58 %$ 118.922  Millions$ 129.861  Millions
Urogen Pharma Ltd   90.93 %$ 65.884  Millions$ 72.456  Millions
Acadia Pharmaceuticals Inc   90.81 %$ 279.643  Millions$ 307.959  Millions
Cytokinetics Incorporated  90.46 %$ 25.893  Millions$ 28.624  Millions
Beone Medicines Ltd   89.76 %$ 1,530.541  Millions$ 1,705.071  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.